Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Completed Phase 4 Interventional Results available

An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.

NCT01873729
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

NCT02675400
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
Vyvanse, Behavioral Parent Training, Methylphenidate
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Assessing a Wearable Digital Therapy for Youth With ADHD

NCT05710965
View directory record Official record
Conditions
ADHD
Interventions
FRx-001, FRx-003, FRx-004
Device
Lead sponsor
Revibe Technologies
Industry
Eligibility
8 Years to 12 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Wake Forest, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 24, 2026, 10:04 PM EDT
Terminated Phase 2 Interventional Results available

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

NCT02261883
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn
Interventions
IV Remodulin, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
1 Hour to 14 Days
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Can Addition of Doxycycline Perioperatively Reduce Propionibacterium Acnes in Shoulder Arthroplasty?

NCT03115177
View directory record Official record
Conditions
Osteoarthritis
Interventions
Doxycycline, Cefazolin
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 90 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 3 Interventional

Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT00030628
View directory record Official record
Conditions
Metastatic Cancer
Interventions
radiation therapy, surgery, WBRT
Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®

NCT00929071
View directory record Official record
Conditions
Aging, Pain
Interventions
Evolence, Lidocaine, topical anesthetic
Device · Drug
Lead sponsor
Weinkle, Susan H., M.D.
Individual
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 24, 2026, 10:04 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

NCT06654037
View directory record Official record
Conditions
Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Abemaciclib, Biopsy Procedure, Biospecimen Collection, Fluorouracil, Radiologic Imaging Procedure
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Irvine, California • Orange, California • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

NCT04143217
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 24, 2026, 10:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

NCT04729959
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Interventions
Atezolizumab, Biospecimen Collection, Conventional Surgery, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Tocilizumab
Biological · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
110
States / cities
Anaheim, California • Bellflower, California • Los Angeles, California + 89 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT04085172
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 10:04 PM EDT
Terminated Not applicable Interventional Results available

Effectiveness of the Quotient® ADHD Assessment in a System of Care

NCT02094612
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders, Attention Deficit Disorder With Hyperactivity
Interventions
Quotient®, Usual Clinic ADHD Care
Device · Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
6 Years to 12 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Folsom, California • Roseville, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products

NCT01313728
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone plus Tretinoin Gel, Tretinoin Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 24, 2026, 10:04 PM EDT
Recruiting Not applicable Interventional

Executive Function and Parenting in Childhood

NCT06241300
View directory record Official record
Conditions
Disruptive Behavior Disorder, Childhood Onset, Disruptive Behavior, Executive Function
Interventions
Chicago Parent Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
4 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity

NCT04969939
View directory record Official record
Conditions
Obesity
Interventions
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Anaheim, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a New Dressing for Use With Topical Medications

NCT00234728
View directory record Official record
Conditions
Psoriasis
Interventions
Occlusive dressing
Device
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

NCT02477332
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
QGE031, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 24, 2026, 10:04 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders

NCT01867398
View directory record Official record
Conditions
Conduct Disorder, fMRI
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
10 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

NCT00679432
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg
Procedure · Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
76
States / cities
Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 24, 2026, 10:04 PM EDT
Withdrawn Phase 4 Interventional

Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate

NCT00931398
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
methylphenidate HCl (Concerta), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Treatment of Youth With ADHD and Anxiety

NCT00012584
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Anxiety, Separation, Social Phobia, Generalized Anxiety Disorder
Interventions
methylphenidate, fluvoxamine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2009 · Synced Oct 24, 2026, 10:04 PM EDT
Recruiting Phase 4 Interventional

Medication Treatment of ADHD in Pediatric Epilepsy

NCT07594652
View directory record Official record
Conditions
ADHD - Attention Deficit Disorder With Hyperactivity
Interventions
methylphenidate hydrochloride (Jornay PM)
Drug
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
6 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 24, 2026, 10:04 PM EDT